美國(guó)波士頓大學(xué)醫(yī)學(xué)院“全國(guó)潛在傳染病實(shí)驗(yàn)室”專家托馬斯·蓋斯伯特領(lǐng)導(dǎo)一個(gè)團(tuán)隊(duì)，選取兩組恒河獼猴應(yīng)用這種試驗(yàn)性藥物。

美國(guó)研究者利用微粒狀基因物質(zhì)干擾埃博拉病毒繁殖的研究取得突破性進(jìn)展。實(shí)驗(yàn)室研究表明，感染埃博拉病毒的恒河獼猴接受一種試驗(yàn)性藥物治療后死亡率降低。

研究人員介紹，這種藥物含有的小型干擾核糖核酸會(huì)抑制酶的誘生，從而達(dá)到干擾病毒繁殖的目的。

研究人員先為*組中3只獼猴注射可致命劑量的埃博拉病毒亞型“埃博拉－扎伊爾”，隨后數(shù)天連續(xù)為這些獼猴注射4劑試驗(yàn)性藥物，結(jié)果其中一只獼猴死亡。

第二組4只獼猴注射同等劑量這種病毒亞型后，連續(xù)接受7劑試驗(yàn)性藥物治療，結(jié)果全部存活。

兩組實(shí)驗(yàn)猴中均有一只獼猴染病后沒有接受試驗(yàn)性藥物治療，zui終死亡。

蓋斯伯特說，這是研究人員制出一種能令非人類靈長(zhǎng)類動(dòng)物感染埃博拉病毒后存活的藥物，具有突破性意義。

“我們認(rèn)為，研究為將這種試驗(yàn)性處方發(fā)展為（批量）制劑、用于埃博拉病例治療提供了論證，無論是在實(shí)驗(yàn)室病毒外泄還是這種疾病暴發(fā)的情形下。”

埃博拉病毒可導(dǎo)致埃博拉病毒出血熱，患者可出現(xiàn)發(fā)熱、惡心、嘔吐、腹瀉、全身酸痛、體內(nèi)外出血等癥狀，致死率可達(dá)90％。

世界衛(wèi)生組織數(shù)據(jù)顯示，自1976年發(fā)現(xiàn)感染埃博拉病毒病例以來，累計(jì)報(bào)告大約1850例這類病例，其中約1200例死亡。

上海勁馬生物（）推薦原文出處：

The Lancet Doi:10.1016/S0140-6736（10）60357-1

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
Prof Thomas W Geisbert PhD a b c , Amy CH Lee MSc e ?, Marjorie Robbins PhD e ?, Joan B Geisbert a, Anna N Honko PhD d, Vandana Sood MSc e, Joshua C Johnson BSc d, Susan de Jong PhD e, Iran Tavakoli BSc e, Adam Judge PhD e, Lisa E Hensley PhD d, Ian MacLachlan PhD e

Background

We previously showed that small interfering RNAs （siRNAs） targeting the Zaire Ebola virus （ZEBOV） RNA polymerase L protein formulated in stable nucleic acid-lipid particles （SNALPs） compley protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever.

Methods

A combination of modified siRNAs targeting the ZEBOV L polymerase （EK-1 mod）, viral protein （VP） 24 （VP24-1160 mod）, and VP35 （VP35-855 mod） were formulated in SNALPs. A group of macaques （n=3） was given these pooled anti-ZEBOV siRNAs （2 mg/kg per dose, bolus intravenous infusion） after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques （n=4） was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV.

Findings

Two （66%） of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection.

Interpretation

This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections.

Funding
Defense Threat Reduction Agency.